Showing 2681-2690 of 2985 results for "".
- Zeltiq Named Top Medical Devices Company in Deloitte's Technology Fast 500™https://practicaldermatology.com/news/20141117-zeltiq_named_top_medical_devices_company_in__deloittes_technology_fast_500/2459063/Ranked among the top 25 companies in Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America, Zeltiq Aesthetics, Inc. is the top ranked
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a
- Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removalhttps://practicaldermatology.com/news/20141103-syneron_candela_announces_fda_clearance_of_picoway_picosecond_laser_for_tattoo_removal/2459076/The FDA granted 510(K) clearance to Syneron Candela's PicoWay picosecond device for tattoo removal. PicoWay is a dual wavelength device, with 1064nm and 532nm wavelengths, which utilizes the proprietary PicoWay Technology to generate picosecond pulses for the removal of tattoos. The FDA clearanc
- INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20141014-inc_research_signs_agreement_to_perform_fda_due_diligence_audit_of_regulatory_documents_for_provectus_biopharmaceuticals/2459085/Provectus Biopharmaceuticals, Inc. has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit will be conducted in two phases, both of which are expected to be
- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- Foamix Pharmaceuticals Ltd. Closes Initial Public Offeringhttps://practicaldermatology.com/news/20140924-foamix_pharmaceuticals_ltd_closes_initial_public_offering/2459104/Foamix Pharmaceuticals Ltd. Closes Initial Public Offering A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The sha
- AppForMyPatients Now Available: Personalized Apps for Aesthetic Practiceshttps://practicaldermatology.com/news/20140922-appformypatients_now_available_personalized_apps_for_aesthetic_practices/2459112/A new patent pending mobile app Nano 2.0 Business Press, LLC aims to allow dermatologists and plastic surgeons to meet the growing patient demand for mobile applications. AppForMyPatients is a software as a service (saas) platform for d
- Curcumin Nanoparticles Prevent Infections in Healing Woundshttps://practicaldermatology.com/news/20140922-curcumin_nanoparticles_prevent_infections_in_healing_wounds/2459114/Curcumin nanoparticles (curc-np) inhibit in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in dose-dependent fashion, and inhibits MRSA growth and enhances wound healing in an in vivo murine wound model, new research in the journal
- The ISDS Awards Scholarships to Young Doctors from Around the Worldhttps://practicaldermatology.com/news/20140917-the_isds_awards_scholarships_to_young_doctors_from_around_the_world/2459117/20 young doctors have been awarded generous scholarships from twenty leaders of the International Society for Dermatologic Surgery (ISDS) to attend an ISDS medical conference. This year, the scholarships were awarded to young doctors from Europe, Asia, Latin America (including Cuba), and